There is increasing evidence that bronchodilators are effective in ventilator dependent preterm infants. The effects of single doses of salbutamol (400 ,ug), ipratropium bromide (72 ,ug), and placebo (four puffs) given by metered dose inhaler and spacer (MDIS) were examined in 10 ventilated preterm infants, with a mean birth weight of 800 g at a postnatal age of 1 week, who were suffering from respiratory distress syndrome. The agents were each given in an open, random design. Blood gases were measured and ventilatory efficiency index (VEI) and arterial/alveolar oxygen tension ratio (Pao2/PAo2) were calculated five minutes before and 30 minutes after administration. Heart rate and mean arterial blood pressure were noted. The mean Pao2 improved by 0-61 kPa and 0-69 kPa after salbutamol and ipratropium bromide, respectively and these changes were significantly greater than the 0.5 kPa fall seen with placebo. The mean arterial carbon dioxide tension fell by 0-98 kPa after salbutamol and 0-59 kPa after ipratropium bromide. After both salbutamol and ipratropium bromide, VEI improved significantly (by 23% and 20% respectively) but there was no significant change in the Pao2/PAo2, suggesting that respiratory mechanics and not ventilation/perfusion balance had improved after a single dose of bronchodilator. We conclude that both salbutamol and ipratropium bromide given by MDIS have useful short term effects in ventilator dependent neonates with respiratory distress syndrome. Precise dose regimens and long term effects remain to be worked out.
We designed this study to examine the clinical effects of two bronchodilator agents, salbutamol and ipratropium bromide administered by MDIS, to preterm infants with respiratory distress syndrome during mechanical ventilation.
Methods

STUDY DESIGN
This was an open, randomised, placebo controlled study of single doses of each of two drugs (salbutamol and ipratropium bromide) administered at intervals of more than eight hours on two or three consecutive days. The outcomes of major interest were arterial blood gases, ventilatory efficiency index (VEI), and arterial/alveolar oxygen tension ratio (PaO2/PAO2). The study was approved by the ethics committee of the Royal Postgraduate Medical School and written parental consent was always obtained.
STUDY POPULATION
Ventilator dependent infants were studied in the neonatal intensive care unit of Hammersmith Hospital and the Meir General Hospital, Kfar Saba, Israel (table 1). The male:female ratio was 4:6. The infants included in this study were less than 34 weeks gestational age at birth, had clinical and radiographic evidence of respiratory distress syndrome, and required mechanical ventilation at the time of study. Three had been given surfactant treatment (Curosurf, Serono) in the interval. The interval between successive drugs was at least eight hours and the order was predetermined using a random number table.
STATISTICAL ANALYSIS For blood gas, VEI, and PaO2/PAo2 data within each drug group, values before and after the dose (log transformed for VEI and Pao2/PAo2) were analysed using paired t test and a p value <0 05 was considered statistically significant. Analysis of variance was used to compare values between drugs, and between time points within drug groups. In the former case, the drugs were regarded as a within subjects factor, and in the latter case, the time points were regarded as a within subjects factor. Individual comparisons were made using t tests based on results of the analysis of variance, using the mean square error and error degree of freedom. The Bonferroni correction was used where appropriate. Because of the small numbers of subjects involved, factorial analysis to assess the possible influence of gestational age, mode of delivery, surfactant treatment and other variables, was not attempted. AEROSOL 
ADMINISTRATION
We used a small volume spacer (Aerochamber MV1 5, Trudell Medical) with a diameter of 4 1 cm, a length of 11 0 cm, a volume of 145 ml and a 15 mm endotracheal tube connector. Metered dose inhalers of salbutamol (Glaxo, 100 jig/puff) and ipratropium bromide (Boehringer Ingelheim, 18 ,ug/puff) or placebo (Glaxo, comprising propellants and lubricants but omitting the active agent) were shaken and inserted into the Aerochamber spacer. The spacer was filled with oxygen and was connected via a manual puffer to an oxygen supply at 8 I/min with an appropriately set blow off valve. Four individual puffs (400 jLg of salbutamol, 72 jig of ipratropium bromide) were delivered at end expiration with five manual breaths between each puff. Routine endotracheal tube suction was not performed for 2-5 hours after administration of each drug, and in fact no subject required suction during this
Results
There was no significant difference in the baseline values of blood gases, VEI, or PaO2/PAO2 between salbutamol, ipratropium bromide, and placebo studies.
After inhalation of salbutamol and ipratropium bromide 8/10 infants showed increases in Pao2 at 30 minutes (fig 1) , resulting in significant mean increases of 0-61 kPa and 0-69 kPa respectively (p<005, table 2). These changes were significantly greater than the mean fall in Pao2 of 0-55 kPa seen after placebo (p<0-017). In 8/10 infants PacO2 fell 30 minutes after inhaled salbutamol (fig 2) , a significant mean decrease of 0-98 kPa (p<005, table 2). Again this change was significantly greater than the fall of 0-02 kPa seen with placebo (p<0 017). Although inhaled ipratropium bromide produced a mean decrease in PacO2 of 0-59 kPa, this was not significantly different from the preinhalation Clinically significant tachycardia, hypotension, or hypertension were not induced in any infant for 2-5 hours after inhalation of salbutamol and ipratropium bromide. The heart rate 30 minutes after inhaled salbutamol was, however, significantly greater than at baseline and the tachycardia appeared to last for two hours (fig 4) , with a maximum mean increase in heart rate of 23 beats/min, 30-60 minutes after administration (fig 4) . After inhaled ipratropium bromide, a smaller increase in heart rate of 14 beats/min was noted at 45 minutes after inhalation (fig 4) . In comparison with changes in heart rate after placebo, salbutamol produced significant increases at 60-90 minutes (p<0007), but the changes in heart rate with ipratropium bromide did not differ from placebo effects. After inhaled salbutamol and ipratropium bromide, the maximum increases in heart rate were observed at median times of 53 and 83 minutes respectively. Salbutamol and ipratropium bromide had no significant effect on mean arterial blood pressure for 2-5 hours after inhalation.
Discussion
We found that in 1 week old preterm, ventilated infants with respiratory distress syndrome, both salbutamol and ipratropium bromide given by MDIS had beneficial effects on blood gases and ventilatory efficiency, 30 minutes after administration. Improvements in oxygenation were not accompanied by significant changes in the Pao2/PAo2 ratio, suggesting that mechanical effects leading to an improvement in ventilatory function rather than alterations in the matching of ventilation and perfusion were responsible for the improvement in Pao2. The degree of improvement, although modest and measured at only one time point, can be considered clinically significant and suggests that further exploration of the role of bronchodilators early in the course of respiratory distress syndrome would be profitable. We decided to study infants at an early stage because of increasing evidence of the efficacy of bronchodilators early in the development of chronic lung disease of prematurity.5 15 during the 30 minute observation e, had no ill effects apart from brief period in the present study, it did not add hypoxaemia. The doses used were to the within subject comparison of changes from direct pulmonary deposition in Paco2. The ratio between tidal volume soluble drugs.'3 Using the MDIS delivered and the ventilator driving pressure ted neonates, we found a mean (respiratoly system compliance) would be deposition of sodium cromoglycate one measure of ventilatory efficiency, but 13 If this figure is applied to the accurate prolonged measurement requires ady, then the pulmonary doses of carefully calibrated equipment. Instead VEI and ipratropium bromide were provides a surrogate for respiratory system g (8 ,ug/kg) and 1-3 ,ug (1.4 pugfkg) compliance which takes into account variation y. These are of the same order as in Paco2.i6 It may also be affected by changes iebulised agents given to children in deadspace and respiratory quotient as its e severe asthma. The prolonged main assumption is that metabolic rate (hence a after salbutamol might suggest carbon dioxide production) is constant over se was rather high. In a preliminary the period of study. This may be untrue after x subjects that we carried out under salbutamol treatment, which could lead to an ircumstances, a dose of salbutamol increase in metabolic rate. If this were the case, (two puffs) had no detectable effect then the measured improvement in VEI after salbutamol would have been underestimated. In the present study, VEI increased signifirabutamol cantly after both salbutamol and ipratropium ratropium bromide bromide, suggesting that pulmonary mechacebo anics and hence the efficiency of alveolar ventilation had improved. This conclusion must be tempered by the possibility that spontaneous breathing effort may have increased after bronchodilator treatment. A word of caution seems appropriate in relation to the changes in airway elastance that might be induced by bronchodilators. The work of Shaffer's group in preterm lamb airways, has demonstrated the susceptibility of tracheal segments to distortion by mechanical ventilation.23 By reducing the elastance of the airways, by removing any support that might be rendered by the tone of the airway smooth muscle, it is possible that deformability might increase, with adverse long term consequences. This has yet to be established in either animal or human lungs in vivo, but should caution against the extrapolation of this single dose study to the long term use of bronchodilators.
It is also important to draw attention to the unknown adverse effects on preterm infants of the propellants and surfactants present in MDIS devices. The small decline in Pao2 after the placebo given by MDIS, without alteration in Paco2, may have been due to these agents.
We conclude that salbutamol and ipratropium bromide given by a small volume spacer (Aerochamber) during intermittent positive pressure ventilation, had a beneficial short term effect on gas exchange and ventilatory efficiency in subacute respiratory distress syndrome in preterm infants without any clinically significant side effects. However, we need further to evaluate the effects of bronchodilator aerosols given by MDIS to infants at various stages and with various degrees of severity of respiratory distress syndrome and chronic lung disease. Dose ranging studies, the effect of drug combinations and the effect of multiple doses are all worthy of investigation. Both the short term outcome, such as a reduction in the need for mechanical ventilation, and the long term benefit of survival free of chronic lung disease should be measured. 
